<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320332</url>
  </required_header>
  <id_info>
    <org_study_id>3291-CL-0003</org_study_id>
    <nct_id>NCT01320332</nct_id>
  </id_info>
  <brief_title>A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of ASP3291 Following a Single Oral Dose in Subjects With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telsar Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telsar Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics (PK) and to assess safety and
      tolerability of a single dose of ASP3291 in subjects with ulcerative colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After an 11-day screening period, subjects check into a clinic, are dosed on Day 1 and stay
      in the clinic for 4 days to monitor pharmacokinetic and safety parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic assessment through analysis of blood, fecal and urine samples</measure>
    <time_frame>Up to Day 4</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>ASP3291 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP3291 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP3291</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>ASP3291 low dose</arm_group_label>
    <arm_group_label>ASP3291 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a previously documented diagnosis of ulcerative colitis (UC) with
             endoscopy and histology consistent with diagnosis

          -  If female, the subject is at least 2 years postmenopausal or is surgically sterile per
             documentation provided by a third party medical professional or the subject agrees to
             use 2 highly effective methods of birth control during the study and is not pregnant
             or lactating

          -  Subject is willing and able to comply with the study requirements

          -  Subject has a body mass index (BMI) of &lt;32 kg/m2

          -  Subject has ulcerative colitis requiring treatment with 5-aminosalicylic acid (5-ASA)

        Exclusion Criteria:

          -  Subject has undergone previous resective colonic surgery

          -  Subject has previously diagnosed Crohn's Disease based on medical history

          -  Subject has an extension of disease limited to ulcerative proctitis

          -  Subject has active peptic ulcer disease based on medical history

          -  Subject is currently being treated with any prescription medication except the
             following: A stable dose of 5-aminosalicylic acid (5-ASA) for at least 2 weeks, oral
             contraceptives or hormone replacement therapy (HRT)

          -  Subject has a history of human immunodeficiency virus (HIV)

          -  Subject has a history of severe allergic or anaphylactic reactions

          -  Subject has a history of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <keyword>ASP3291</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

